The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected to neutralize omicron subvariants BQ.1 and BQ.1.1. While bebtelovimab remains authorized in all U.S. regions until further notice, prescribers should monitor the Centers for Disease Control and Prevention’s regional variant frequency data and refer to the provider fact sheet for details regarding resistance against SARS-CoV-2 variants in their area, FDA said

In other news, FDA yesterday warned health care professionals that naloxone may not be able to reverse the effects of xylazine in fentanyl, heroin and other illicit drug overdoses. FDA is aware of increasing reports of serious side effects from individuals exposed to fentanyl, heroin and other illicit drugs contaminated with xylazine, a sedative and pain reliever that FDA has approved for use in animals.

Related News Articles

Perspective
As we move into fall and winter, we know the viruses that cause respiratory disease will usually circulate more heavily in communities. Already, the Centers…
Headline
In these video snippets from an AHA Advancing Health podcast series, health care leaders and clinicians from four children's hospitals share how they worked to…
Headline
Most health insurers must cover the updated COVID-19 vaccines from Pfizer and Moderna without cost sharing effective Sept. 11, when the Food and Drug…
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…